Related Experiment Videos
Novel retrovirus protease inhibitors, RPI-856 A, B, C and D, produced by Streptomyces sp. AL-322
1Discovery Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan.
Abstract:
Four kinds of retrovirus protease inhibitors (RPI-856 A, B, C and D) were isolated as white powder from the culture filtrate of a soil isolate, Streptomyces sp. AL-322 by column chromatography using Diaion HP-20, Sephadex LH-20, ODS reversed phase HPLC and SP-2SW ion exchange HPLC. The structures of these inhibitors were elucidated by physico-chemical properties, chemical reactions and spectral analyses, as valyl-ADPAA-leucyl-AOPBA-valyl-valyl-aspartic acid (RPI-856 A and B) and valyl-ADPAA-leucyl-AOPBA-valyl-valine (RPI-856 C and D) [ADPAA = 2-amino-2-(3,5-dihydroxyphenyl)acetic acid, AOPBA = 3-amino-2-oxo-4-phenylbutyric acid]. RPI-856 A and B, and RPI-856 C and D were both determined to be diasteromers each other on the asymmetric carbon in AOPBA. These four inhibitors strongly inhibited in vitro HIV-1 protease and HTLV-I protease both derived from recombinant Escherichia coli with IC50 of 10(-7) approximately 10(-8) M.
Insights
Soil bacteria Streptomyces sp. AL-322 produced four retrovirus protease inhibitors (RPI-856 A-D). These compounds effectively inhibited HIV-1 and HTLV-I proteases in vitro, showing potential as antiviral agents.
Area of Science:
- Microbiology
- Biochemistry
- Pharmacology
Background:
- Retroviruses, such as HIV-1 and HTLV-I, pose significant global health challenges.
- Protease inhibitors are crucial for managing retroviral infections by blocking viral replication.
- Novel sources for discovering effective antiviral compounds are continuously sought.
Purpose of the Study:
- To isolate and characterize novel retrovirus protease inhibitors from a soil microorganism.
- To elucidate the chemical structures of the isolated compounds.
- To evaluate the in vitro inhibitory activity of these compounds against HIV-1 and HTLV-I proteases.
Main Methods:
- Isolation of compounds using column chromatography (Diaion HP-20, Sephadex LH-20) and High-Performance Liquid Chromatography (HPLC).
- Structure elucidation through physico-chemical properties, chemical reactions, and spectral analyses.
- In vitro enzyme inhibition assays using recombinant HIV-1 and HTLV-I proteases.
Main Results:
- Four retrovirus protease inhibitors (RPI-856 A, B, C, and D) were isolated from Streptomyces sp. AL-322.
- The structures were determined as valyl-ADPAA-leucyl-AOPBA-valyl-valyl-aspartic acid (RPI-856 A and B) and valyl-ADPAA-leucyl-AOPBA-valyl-valine (RPI-856 C and D).
- RPI-856 A/B and RPI-856 C/D were identified as diastereomers. All four compounds exhibited potent in vitro inhibition of HIV-1 and HTLV-I proteases with IC50 values in the range of 10(-7) to 10(-8) M.
Conclusions:
- Streptomyces sp. AL-322 is a source of novel retrovirus protease inhibitors.
- The identified compounds, RPI-856 A-D, demonstrate significant potential for development as antiviral therapeutics against HIV-1 and HTLV-I.
- Further research into the mechanism of action and in vivo efficacy of these inhibitors is warranted.